Researchers develop treatment to prevent developmental retardation, autism


A report published by the Tel Aviv University on Thursday states that Israeli researchers have developed a treatment that could prevent developmental lag and autism. According to the statements report Xinhua Net, the study was carried out with the mouse model. They found that early treatment with NAP (Nucleoside Compounding Neptide) peptide normalizes the development of ADNP associated syndrome (depending on the activity that depends on neuroprotective proteins) in children. One of the major causes of developmental delay and autism in children is genetic mutation.

Gen ADNP plays a role in the development of cognition. In most cases, embryos with a partial lack of ADNP will suffer mental retardation and autism.

In recent years, autistic children with mental retardation have had random mutations in the ADNP gene, with the development of a genetic sequence technology that appears to occur during pregnancy.

The resulting protein is shorter than usual, and children suffer from incomplete ADNP (which is ADNP syndrome).

According to the report, researchers found that mice with ADNP produce only about half the number of synapses (nerve cell linking points) compared to healthy mice – especially in brain areas that are responsible for cognitive activity.

These mice showed developmental delay, social problems and sensitivity, such as children with mental retardation and autism.

In the next stage, followed by a spray of mice sprays that were discharged from breastfeeding, the NAP peptide was injected daily into the affected mice from the moment of birth.

However, the results were very impressive: the treated mice developed normally. They could have distinguished between known and unknown mice, had proper memory, and developed muscle strength. In fact, these brains began to produce an appropriate number of synapses.

Posted: November 16, 2018 14:42

Source link